<DOC>
	<DOCNO>NCT00802334</DOCNO>
	<brief_summary>Evaluating bioavailibility safety efficacy generic LPV/RTV 200/50 mg tablet formulation 400/100 mg BID dose Thai HIV infected individual .</brief_summary>
	<brief_title>TDM Generic Lopinavir/Ritonavir 200/50 mg</brief_title>
	<detailed_description>The original solid oral formulation lopinavir/ritonavir soft gel capsule ( SGC ) 133/33 mg formulation . This formulation require refrigerate storage need administer food [ 4 ] . Recently Abbott develop new formulation fix combination , 200/50 mg tablet ( Aluvia ) . This formulation show bioequivalence old formulation , n't need refrigerated storage diminish food effect [ 5 ] . This profound advantage develop world , till Aluvia available Thailand yet , , price might issue HIV-infected Thai patient . The Indian company Matrix produce generic formulation Abbott 's Aluvia . In Indian healthy volunteer tablet formulation proven bioequivalent Abbott 's Aluvia 400/100 mg bid dosing ( unpublished data ) . Implementing drug Thai clinical practice save huge amount cost , result , make second line regimen accessible Thai HIV-infected population . We expect BE data Indian population extrapolate Thai population , confirm order register drug Thailand extensive therapeutic drug monitoring ( TDM ) 100 patient do . To meet regulatory criterion HIVNAT coordinate ass TDM trial Thai HIV-infected patient eligible use generic 200/50 mg lopinavir/ritonavir tablet 200/50 mg . This open-label , single-center phase-II trial 100 HIV-infected subject . Patients either treatment-na√Øve treatment-experienced enter clinical trial . After meet in- exclusion criterion , patient start lopinavir/ritonavir new formulation 400/100 mg bid low fat diet , plus 2 nucleoside reverse transcriptase inhibitor ( NRTIs ) . The choice 2 NRTIs discretion investigator . Only patient Kaletra SGC undergo TDM sample baseline . Although paper Klein et al . show diminished food effect [ 5 ] still advice patient take food , data generic product become available , confirm lack food effect pharmacokinetics . Once patient include ( generic ) lopinavir/ritonavir base regimen design initiated . Patients Kaletra SGC base regimen baseline undergo TDM base line . Therapeutic drug monitoring lopinavir do 4 week , ensure steady state . At baseline week 4 safety data obtain . After first 30 patient show good bioavailibility , 70 subject follow total 48 week obtain safety efficacy data</detailed_description>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<criteria>1 . Signed informed consent 2 . Evidence HIV infection ( confirm positive ELISA and/or document history measurable HIV RNA ) 3 . Age &gt; 18 year 4 . On standard PI contain HAART regimen 2 NRTIs VL &lt; 50 copy least 12 week OR ARVnaive patient , patient NNRTI base regimen 5 . Currently AIDS define illness 6 . Willing adhere protocol requirement 1 . Any history take CYP450 inhibitor inducer , gastric acidreducing drug within 14 day enrollment study 2 . Current pregnancy lactate 3 . Active opportunistic infection 4 . ALT/ AST 2 x upper limit 5. creatinine 1.5 time upper limit 6 . Relevant history current condition , illness might interfere drug absorption , distribution , metabolism excretion 7 . History sensitivity/idiosyncrasy drug chemically related compound excipients may employ study . 8 . Active drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>generic lopinavir/ritonavir</keyword>
	<keyword>therapeutic drug monitoring</keyword>
	<keyword>safety efficacy</keyword>
</DOC>